Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis

BACKGROUND: This network meta-analysis aimed to assess the comparative efficacy and safety of combinations involving three cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapies (ETs) in patients with metastatic or advanced breast cancer (BC) who are hormone receptor-positive (HR+)...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yiyuan, Wu, Jinyao, Ji, Zeqi, Chen, Lingzhi, Zou, Juan, Zheng, Jiehua, Lin, Weixun, Cai, Jiehui, Chen, Yaokun, Zheng, Daitian, Chen, Yexi, Li, Zhiyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469949/
https://www.ncbi.nlm.nih.gov/pubmed/37653504
http://dx.doi.org/10.1186/s12885-023-11322-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469949/
https://www.ncbi.nlm.nih.gov/pubmed/37653504
http://dx.doi.org/10.1186/s12885-023-11322-2

Ejemplares similares